Guggenheim Forecasts Strong Price Appreciation for CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics (NASDAQ:CTMX) had its price objective increased by equities research analysts at Guggenheim from $10.00 to $15.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price target would indicate a potential upside of 214.80% from the stock’s previous close.

CTMX has been the topic of several other reports. Piper Sandler upped their price objective on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Wedbush boosted their price target on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday. Barclays increased their price target on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Cantor Fitzgerald raised their price objective on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Finally, HC Wainwright lifted their price objective on shares of CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Monday. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.22.

CytomX Therapeutics Stock Up 8.3%

CytomX Therapeutics stock opened at $4.77 on Wednesday. The stock has a market cap of $810.96 million, a price-to-earnings ratio of -119.13 and a beta of 2.44. The business has a 50-day simple moving average of $5.28 and a 200 day simple moving average of $4.10. CytomX Therapeutics has a 52 week low of $0.40 and a 52 week high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The business had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. On average, research analysts anticipate that CytomX Therapeutics will post -0.05 earnings per share for the current year.

Insider Transactions at CytomX Therapeutics

In other CytomX Therapeutics news, CFO Christopher Ogden sold 19,323 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $124,053.66. Following the completion of the sale, the chief financial officer owned 296,948 shares of the company’s stock, valued at $1,906,406.16. This represents a 6.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Marcia Belvin sold 31,492 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $202,178.64. Following the transaction, the senior vice president owned 300,760 shares in the company, valued at $1,930,879.20. The trade was a 9.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 191,063 shares of company stock worth $1,226,624. 6.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CytomX Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CTMX. Orbimed Advisors LLC bought a new stake in CytomX Therapeutics in the second quarter worth $19,208,000. Commodore Capital LP bought a new position in shares of CytomX Therapeutics during the second quarter valued at about $17,462,000. Perceptive Advisors LLC purchased a new position in shares of CytomX Therapeutics in the second quarter worth about $15,876,000. Vivo Capital LLC purchased a new position in shares of CytomX Therapeutics in the second quarter worth about $13,096,000. Finally, Franklin Resources Inc. bought a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at about $13,096,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Several brokerages raised ratings/targets, boosting sentiment — Barclays raised its target to $16 (overweight). Article Title
• Positive Sentiment: Guggenheim increased its price target to $15 and kept a Buy rating, supporting upside expectations. Article Title
• Positive Sentiment: Wedbush raised its price target to $11, and JPMorgan reportedly upgraded the stock — multiple upgrades are driving positive analyst momentum. Wedbush Article JPMorgan Article
• Neutral Sentiment: HC Wainwright cut near‑term EPS forecasts (Q1–Q4 2026 and FY2026/2027) but retained a Buy rating and a $17 target — mixed signal (lowered estimates but continued bullish view). MarketBeat Report
• Neutral Sentiment: Short-interest data in the feed appears anomalous (shows zero shares) and likely does not provide meaningful directional signal today.
• Negative Sentiment: CytomX priced an underwritten offering of common stock and pre‑funded warrants to raise up to $250M gross (closing expected March 19); markets often view such equity raises as dilutive, which can pressure the stock despite providing runway for trials. Offering Release
• Negative Sentiment: Related coverage notes net proceeds of about $234M from the offering — confirms material dilution magnitude and why some traders sold into the raise. TipRanks Article
• Negative Sentiment: Insider selling: CFO Christopher Ogden sold 19,323 shares and SVP Marcia Belvin sold 31,492 shares on March 17 — disclosed on SEC Form 4 filings; insider sales can be read negatively by the market. CFO Form 4 SVP Form 4
• Negative Sentiment: Recent quarterly results missed expectations (EPS and revenue), which was cited as a reason for an intra‑day pullback earlier this week. Earnings Reaction

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.